# ![@LabbRadar Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1663627994135404545.png) @LabbRadar LabRadar 🇮🇱 🇺🇦

LabRadar 🇮🇱 🇺🇦 posts on X about $clbr, $pew, $isrl, $nvct the most. They currently have [------] followers and [----] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1663627994135404545/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1663627994135404545/c:line/m:interactions.svg)

- [--] Week [------] +241,940%
- [--] Month [------] -100%
- [--] Months [----------] +7,171%
- [--] Year [----------] +21,181%

### Mentions: [--] [#](/creator/twitter::1663627994135404545/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1663627994135404545/c:line/m:posts_active.svg)

- [--] Month [--] -97%
- [--] Months [---] -64%
- [--] Year [-----] +167%

### Followers: [------] [#](/creator/twitter::1663627994135404545/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1663627994135404545/c:line/m:followers.svg)

- [--] Week [-----] +0.23%
- [--] Month [-----] +0.13%
- [--] Months [-----] -3.40%
- [--] Year [-----] +33%

### CreatorRank: [-------] [#](/creator/twitter::1663627994135404545/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1663627994135404545/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  [cryptocurrencies](/list/cryptocurrencies)  [stocks](/list/stocks)  [countries](/list/countries)  [currencies](/list/currencies)  [exchanges](/list/exchanges)  [technology brands](/list/technology-brands)  [travel destinations](/list/travel-destinations)  [social networks](/list/social-networks)  [us election](/list/us-election) 

**Social topic influence**
[$clbr](/topic/$clbr), [$pew](/topic/$pew), [$isrl](/topic/$isrl), [$nvct](/topic/$nvct) #7, [$isrlw](/topic/$isrlw), [$iinn](/topic/$iinn), [$gsrt](/topic/$gsrt), [$gkprf](/topic/$gkprf), [$clbrws](/topic/$clbrws), [market cap](/topic/market-cap)

**Top accounts mentioned or mentioned by**
[@trustmebroclown](/creator/undefined) [@jabroniville69](/creator/undefined) [@chaserx911](/creator/undefined) [@rinoballz](/creator/undefined) [@bettacallsaul](/creator/undefined) [@realomeedmalik](/creator/undefined) [@donaldjtrumpjr](/creator/undefined) [@grabagun](/creator/undefined) [@monacobiotech](/creator/undefined) [@kurtvonnecatjr](/creator/undefined) [@maximusholla](/creator/undefined) [@erictheumpire](/creator/undefined) [@amaymd](/creator/undefined) [@stocktwits](/creator/undefined) [@cobraalerts](/creator/undefined) [@stepnotonpets](/creator/undefined) [@arenella1](/creator/undefined) [@shravanrayhaan](/creator/undefined) [@clbrspac](/creator/undefined) [@vulturetrades](/creator/undefined)

**Top assets mentioned**
[pepe in a memes world (PEW)](/topic/$pew) [Nuvectis Pharma, Inc.  (NVCT)](/topic/$nvct) [Inspira Technologies OXY B.H.N. Ltd (IINN)](/topic/$iinn) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Bull Market (BULL)](/topic/$bull) [uniQure N.V. (QURE)](/topic/$qure) [Pfizer, Inc. (PFE)](/topic/$pfe) [Arvinas, Inc (ARVN)](/topic/$arvn) [AstraZeneca PLC (AZN)](/topic/$azn) [Oklo Inc. (OKLO)](/topic/$oklo) [Soleno Therapeutics, Inc. Common Stock (SLNO)](/topic/$slno) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Newsmax Inc (NMAX)](/topic/$nmax) [Recursion Pharmaceuticals, Inc. (RXRX)](/topic/$rxrx) [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Intellia Therapeutics, Inc (NTLA)](/topic/$ntla) [TrumpCoin (DJT)](/topic/$djt) [Vertex Protocol (VRTX)](/topic/$vrtx) [Core Scientific, Inc. Common Stock (CORZ)](/topic/$corz) [Columbus Circle Capital Corp I Class A Ordinary Shares (CCCM)](/topic/$cccm) [NexGel Inc. (NXGL)](/topic/$nxgl) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Rally (RLY)](/topic/rally) [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Eli Lilly and Company (LLY)](/topic/$lly)
### Top Social Posts
Top posts by engagements in the last [--] hours

"3/ If $PFE acquired shares or shares+warrants they must file a 13G/A within [--] days due to exceeding the 10% ownership threshold. Could they have strategically repurchased a portion of their $492mm obligation at a favorable price"  
[X Link](https://x.com/LabbRadar/status/1663710429430833152)  2023-05-31T00:54Z [---] followers, [--] engagements


"$SRZN $1.55 per share cash/ no debt. 30M shares. Column Group with 30%. Down hard after Q2 update. Leader Wnt biology. [--] P1 drugs w data YE. Preclinical deal w BI. Runway just extended into [--]. CEO ex Jazz Pharma"  
[X Link](https://x.com/LabbRadar/status/1691174927452254208)  2023-08-14T19:48Z [---] followers, [---] engagements


"Sometimes you just cant do any more due diligence. The wealth is made sitting on your hands keeping the conviction and waiting patiently"  
[X Link](https://x.com/LabbRadar/status/1704944748925264224)  2023-09-21T19:44Z [---] followers, [--] engagements


"Sold $uncy +34% gainer yesterday & also moved it over to $NVCT forgot to mention"  
[X Link](https://x.com/LabbRadar/status/1707414681239851196)  2023-09-28T15:19Z [---] followers, [--] engagements


"Despite significant insider buys and promising data the market appears cautious about adoption speed. Hospital contracts and traction post-placement remain key factors. PMA approval for LungFit PH solidifies the platform's potential. #MarketAnalysis"  
[X Link](https://x.com/LabbRadar/status/1707451342636384461)  2023-09-28T17:44Z [---] followers, [--] engagements


"Management's confidence and extensive insider buying raised expectations potentially leading to disappointment. Patience is crucial as the phased rollout allows for modeling of business units. NTM partnership likely due to trial costs and substantial TAM. #patience"  
[X Link](https://x.com/LabbRadar/status/1707451344641262023)  2023-09-28T17:44Z [---] followers, [---] engagements


"In an era where therapeutic breakthroughs hold unprecedented value scarcity imparts a distinct premium. Indications boasting but a solitary or pair of therapies conspicuously eclipsing standard of care merit a valuation akin to that which forged the ascendancy of giants like"  
[X Link](https://x.com/LabbRadar/status/1707471439505551606)  2023-09-28T19:04Z [----] followers, [--] engagements


"$VRTX $ALNY $ARGX $AXSM $ALXN etc. The genesis of such powerhouses lies not in the accretion of myriad ventures but in the astute elevation of singular transformative modalities. #BiotechValuation #TherapeuticAdvancements"  
[X Link](https://x.com/LabbRadar/status/1707471442575782261)  2023-09-28T19:04Z [----] followers, [---] engagements


"This may precipitate a surge in sales come Q2 engendering a rekindling of investor fervor for commercial-stage biotechnology. Amidst this transformative landscape pivotal deal dynamics are poised to reshape the industry:"  
[X Link](https://x.com/LabbRadar/status/1707471446451356018)  2023-09-28T19:04Z [---] followers, [--] engagements


"1. M&A Surge in Commercial-Stage BiotechPharma's substantial resources and nascent biotechs' tailored therapeutics yield scarcity value sparking competitive mergers and acquisitions. [--]. Global Licensing AgreementsBiotechs may opt for international rights exchange to sidestep"  
[X Link](https://x.com/LabbRadar/status/1707471449328644498)  2023-09-28T19:04Z [----] followers, [--] engagements


"The evolution of Palestinian identity from being viewed as part of a broader Arab identity to the development of distinct Palestinian nationalism underscores the intricate nature of this narrative. Recognizing this transformation is crucial in understanding the conflict. #Arabs"  
[X Link](https://x.com/LabbRadar/status/1712119459375439904)  2023-10-11T14:54Z [---] followers, [--] engagements


"Moments of hope like the Oslo Accords and the tragic turn of events during the Second Intifada are critical junctures in this narrative. These pivotal moments have profoundly influenced subsequent policies and approaches. #PeaceProcess #OsloAccords"  
[X Link](https://x.com/LabbRadar/status/1712119460558163986)  2023-10-11T14:54Z [---] followers, [--] engagements


"Beyond leadership the pivotal involvement of the GOG Foundation & Dr. Bradley Monk in 800s development provides reassurance of its potential. The fact that insiders & key investors hold around 70% of $NVCT shares speaks volumes about their conviction in the company's trajectory"  
[X Link](https://x.com/LabbRadar/status/1717972810008858961)  2023-10-27T18:33Z [----] followers, [---] engagements


"$NVCT This limited float leaves a prime opportunity for discerning retail investors. The strategic timing of these purchases suggests that those in the know might have access to positive open-label data slated for reporting in 1Q24"  
[X Link](https://x.com/LabbRadar/status/1717972812156252205)  2023-10-27T18:33Z [----] followers, [---] engagements


"The optimism surrounding $TGTX intensifies as it gains traction with Ocrevus switches attributed in part to the "efficacy gap". Furthermore the involvement of esteemed Academic centers now equipped with the J-Code bolsters this positive momentum"  
[X Link](https://x.com/LabbRadar/status/1719829530016088105)  2023-11-01T21:31Z [---] followers, [---] engagements


"The undervaluation may stem from a dearth of investor cognizance and perhaps the enduring scepticism surrounding South Korean entities listed in U.S. markets. Nevertheless $GRVY's performance metrics resonate strongly"  
[X Link](https://x.com/LabbRadar/status/1719837064123064629)  2023-11-01T22:01Z [---] followers, [---] engagements


"Intriguing dynamics at play today for $TGTX. A substantial short covering on ER day but new shorts might find themselves in a precarious position. With 27% of the float short there's potential for a strong squeeze"  
[X Link](https://x.com/LabbRadar/status/1720468140868378708)  2023-11-03T15:49Z [---] followers, [----] engagements


"CEO Weiss' strategic shift away from Symphony is a shrewd move likely to paint a clearer revenue picture. Analysts and retail may have underestimated the actual figures which once revealed could propel $TGTX to new heights"  
[X Link](https://x.com/LabbRadar/status/1720468143263350979)  2023-11-03T15:49Z [---] followers, [---] engagements


"Distinguishing between offensive & defensive violence is #paramount in understanding the #israelpalestine #conflict. Media narratives often paint a simplified picture overlooking the intricate context. Tragedy befalls both sides underscoring the brutal toll of conflict. #Hamas"  
[X Link](https://x.com/LabbRadar/status/1720477431490875646)  2023-11-03T16:25Z [---] followers, [---] engagements


"$TGTX Additionally they shed light on the issue of non-compliance with pills in multiple sclerosis (MS) patients. This insight underscores the perceived superiority of IV treatment"  
[X Link](https://x.com/LabbRadar/status/1720858884754071976)  2023-11-04T17:41Z [---] followers, [---] engagements


"$TGTX Impressive 62% surge last week is indicative of the triple-digit growth in sales and earnings per share (EPS) following their European drug licensing"  
[X Link](https://x.com/LabbRadar/status/1720858887761383918)  2023-11-04T17:41Z [---] followers, [---] engagements


"@HarveyGingras @SpikeMilligan29 @WabKinew Why are you bringing up First Nations nonsense up when were talking about the Israel-Palestine conflict Zero relevance. Nice try Harvey. Keep both your chins up high Maybe next time youll come up with some better :)"  
[X Link](https://x.com/LabbRadar/status/1721004176807698693)  2023-11-05T03:19Z [---] followers, [---] engagements


"It's imperative to clarify that $APLS has never laid claim to a complete cure for GA; rather it has shown promise in significantly decelerating the progression of GA over the long term"  
[X Link](https://x.com/LabbRadar/status/1721569321212928050)  2023-11-06T16:44Z [----] followers, [---] engagements


"$APLS In this particular niche of degenerative eye diseases there is currently no palpable competition. Notably $ISEE/Astella's offering though promising is only approved for a duration of less than a year"  
[X Link](https://x.com/LabbRadar/status/1721569323817513458)  2023-11-06T16:44Z [----] followers, [---] engagements


"1/ In the small-cap bio arena success often hinges not just on the strength of the product but also on terms and timing. The prospect of a buyout for remaining rights to Setrusumab given its stellar data looms inevitable for $MREO"  
[X Link](https://x.com/LabbRadar/status/1721578853876035588)  2023-11-06T17:22Z [---] followers, [---] engagements


"A nuanced evaluation of $MREO's strategic landscape unveils a clear trajectory: Setrusumab's stellar results and the potential for label expansion beyond OI have altered the game"  
[X Link](https://x.com/LabbRadar/status/1721578858875670708)  2023-11-06T17:22Z [---] followers, [---] engagements


"Osteoporosis poised to assail $AMGN's multibillion-dollar franchises presents a promising future for Setrusumab. $MREO"  
[X Link](https://x.com/LabbRadar/status/1721578861450928258)  2023-11-06T17:22Z [---] followers, [---] engagements


"@Bernard22190947 Its a long term investment as noted from the beginning I think it could end being an extraordinary investment. I see zero risk which ironically makes me nervous because I dont know if Im not seeing something I should be. I think itll 30-50x and thats conservative"  
[X Link](https://x.com/LabbRadar/status/1722008255952502834)  2023-11-07T21:48Z [---] followers, [--] engagements


"How ironic is it that its so many BLM Supporters & 🏳🌈 supporters that are celebrating the war crimes committed by Hamas on Oct.7. Little do these people know that Hamas hates LGBTQ+ people & would love to murder them"  
[X Link](https://x.com/LabbRadar/status/1722395975480734128)  2023-11-08T23:29Z [---] followers, [--] engagements


"$TGTX gotta think some bids coming in near future. I dont see much (if any) risks & its historically been infested with shorts playing games & scare tactics"  
[X Link](https://x.com/anyuser/status/1723041449246126465)  2023-11-10T18:14Z [----] followers, [----] engagements


"Which name has the most upside at current levels: [--]. $SOFI [--]. $ASTS [--]. $SHOT [--]. $EOSE Feel free to comment why you voted for the name you voted for. Cheers 🍻"  
[X Link](https://x.com/LabbRadar/status/1727062827830219164)  2023-11-21T20:34Z [---] followers, [---] engagements


"$PDSB enthusiasts whats your final price targets"  
[X Link](https://x.com/LabbRadar/status/1727712701621645640)  2023-11-23T15:36Z [---] followers, [----] engagements


"$XBI What is everyones thoughts on biotech sentiment at present moment [--]. Lots more carnage to come [--]. Some more short term carnage but we are getting close to the bottom [--]. At the bottom now but will trade sideways for awhile [--]. At bottom now- approaching huge bull trend"  
[X Link](https://x.com/LabbRadar/status/1728088384596296039)  2023-11-24T16:29Z [---] followers, [---] engagements


"$XBI $AXSM $PFE $MRNA $ICVX $TGTX $MREO $SPY $SHOT $NVOS $GYRE $CBIO $AXLA $CYCN The polls are getting spicy 🌶"  
[X Link](https://x.com/LabbRadar/status/1728154354450833908)  2023-11-24T20:51Z [---] followers, [----] engagements


"As I navigate this ideological shift the imperative remains to uphold democratic ideals champion individual freedoms and stand against the ominous specter of ideologies that compromise the very essence of these principles"  
[X Link](https://x.com/LabbRadar/status/1728608016214249799)  2023-11-26T02:54Z [---] followers, [--] engagements


"@Bernard22190947 I understand what youre saying but when you look at the mass protests being held a significant portion of them are held by far left activists - the same mobs as the BLM mobs. Although I dont support MAGA in general Im not seeing anti-Semitic MAGA mobs to the same extent"  
[X Link](https://x.com/LabbRadar/status/1728852291632185509)  2023-11-26T19:04Z [---] followers, [--] engagements


"@Bernard22190947 I find it ironic how many BLM and LGBTQ protesters alike call themselves human rights activist with one sign and then hold up another sign drawing parallels between the IDF defending itself and the Nazi party. These protesters are surely naive to how Hamas would treat them"  
[X Link](https://x.com/LabbRadar/status/1728853271446720960)  2023-11-26T19:08Z [---] followers, [--] engagements


"Rest in Peace Charlie Munger You wrote one of my favourite books Ive ever read; the Tao of Charlie Munger. Thanks for all your wisdom"  
[X Link](https://x.com/LabbRadar/status/1729648999144063075)  2023-11-28T23:50Z [---] followers, [---] engagements


"In [----] at [--] Charlie Munger joined Wright & Garrett for $3300/year $29851 adjusted for inflation. With $1500 savings equivalent to $13570 today"  
[X Link](https://x.com/LabbRadar/status/1729727581564329990)  2023-11-29T05:02Z [---] followers, [---] engagements


"Life threw more challenges. Munger later underwent a painful operation losing sight in one eye. Yet by [--] he emerged as one of the world's wealthiest married for 35+ years with a large family and revered as a profound business thinker"  
[X Link](https://x.com/LabbRadar/status/1729727592951877765)  2023-11-29T05:02Z [---] followers, [--] engagements


"Charlie Munger's journey teaches resilience triumph over adversity and the enduring power of perseverance. From hardship to wealth his story is one of extraordinary resilience and ultimate success"  
[X Link](https://x.com/LabbRadar/status/1729727596030538124)  2023-11-29T05:02Z [---] followers, [--] engagements


"Proposing an amalgamation of $VERO & $CUTR a strategic move to curtail redundant costs and steer towards profitability. Envisioning a united entity generating $400 million in revenue with approximately 65% gross margins upon realignment"  
[X Link](https://x.com/LabbRadar/status/1731699669120540842)  2023-12-04T15:39Z [---] followers, [---] engagements


"$CUTR $VERO Both entities converging toward cash flow break-even this synergy eliminates duplicated R&D propelling the foremost platforms"  
[X Link](https://x.com/LabbRadar/status/1731699672568287391)  2023-12-04T15:39Z [---] followers, [---] engagements


"Engaged in the Fireside chat with Lisi regarding $XAIR a palpable shift in demeanor noted compared to the recent earnings call. Lisi fervent and resolute expressed intent to seize market share and dominate the sector"  
[X Link](https://x.com/LabbRadar/status/1731702729402163574)  2023-12-04T15:51Z [---] followers, [---] engagements


"Puzzled by the perceived undervaluation of $XAIR he acknowledged team-wide frustration over regulatory delays attributing setbacks to the pandemic-induced disruptions. While cautiously sidestepping specific timelines Lisi alluded to a resurgence of normalcy"  
[X Link](https://x.com/LabbRadar/status/1731702734342996088)  2023-12-04T15:51Z [---] followers, [--] engagements


"$XAIR Management's declaration of significant revenue post-March [----] does little to assuage apprehensions. With a projected meager $14 million in revs between March [----] & March [----] heightened expenses and persistent high cash burn throughout [----] hint at a challenging year"  
[X Link](https://x.com/LabbRadar/status/1731702745197883843)  2023-12-04T15:51Z [---] followers, [---] engagements


"$XAIR The inevitability of substantial dilution looms large posing a risk of sub-$1 valuation and Nasdaq compliance breach given the current small market cap"  
[X Link](https://x.com/LabbRadar/status/1731702747068617148)  2023-12-04T15:51Z [---] followers, [---] engagements


"@sunlorrie When you try to please everyone you end up pleasing no one - a quote that perfectly epitomizes Trudeaus [--] years as Prime Minister"  
[X Link](https://x.com/LabbRadar/status/1733153406502514808)  2023-12-08T15:55Z [---] followers, [--] engagements


"$TGTX In the expansive landscape of MS where 80K patients annually embark on new therapies anti-CD20s claim their dominance. W/ BRIUMVI at the forefront challenging Ocrevus the scenario points toward anti-CD20s becoming the go-to treatment capturing the lion's share of this"  
[X Link](https://x.com/LabbRadar/status/1733161781785461151)  2023-12-08T16:29Z [---] followers, [---] engagements


"colossal market. Amidst the speculative air $MRK looms as a potential suitor for $TGTX. The prospect of a bidding war adds a layer of intrigue. As BRIUMVI charts its course Symphony Trx data becomes the navigational tool offering insights into the mkt dynamics & the potential"  
[X Link](https://x.com/LabbRadar/status/1733161783920304181)  2023-12-08T16:29Z [---] followers, [---] engagements


"$VRTX shares groundbreaking outcomes from the Phase [--] study of VX-548 a selective NaV1.8 inhibitor showing a significant and meaningful reduction in neuropathic pain"  
[X Link](https://x.com/LabbRadar/status/1734991095270969497)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX VX-548 stands out with a favorable safety profile. Mild to moderate adverse events no serious concerns. Promising news for a well-tolerated treatment option in the challenging realm of neuropathic pain"  
[X Link](https://x.com/LabbRadar/status/1734991096982200510)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX plans to propel VX-548 into pivotal development for diabetic peripheral neuropathic pain. Discussions with regulators will shape this next phase"  
[X Link](https://x.com/LabbRadar/status/1734991099502960884)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX initiates a Phase [--] study for VX-548 in painful lumbosacral radiculopathy (LSR) expanding its applications in peripheral neuropathic pain. Their multi-pronged approach positions it at the forefront of pain management"  
[X Link](https://x.com/LabbRadar/status/1734991101801431079)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX VX-548 shows robust pain reduction across all doses with a notable responder rate. Over 30% achieve 50% reduction in pain suggesting a promising impact on neuropathic pain relief"  
[X Link](https://x.com/LabbRadar/status/1734991104028676127)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX KOLs like Dr. Roy Freeman express excitement over Phase [--] results foreseeing VX-548 as a milestone in pain management. Recognition of promising safety and efficacy profiles elevates its potential impact"  
[X Link](https://x.com/LabbRadar/status/1734991105731551239)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX is committed to advancing NaV1.8 and NaV1.7 inhibitors positioning itself at the forefront of pain management innovation. Strategic vision aligns with addressing acute and neuropathic pain challenges"  
[X Link](https://x.com/LabbRadar/status/1734991107430195395)  2023-12-13T17:38Z [---] followers, [--] engagements


"$VRTX Interesting investor call today"  
[X Link](https://x.com/LabbRadar/status/1734991109070225595)  2023-12-13T17:38Z [---] followers, [--] engagements


"@Phoenix3million Me 🙋♂"  
[X Link](https://x.com/anyuser/status/1740397104466452488)  2023-12-28T15:39Z [--] followers, [--] engagements


"Joel Greenblatt highlights that even billion-dollar institutional funds struggle to outperform due to the efficiency-focused competition among professionals. $NVCT's unique thin float/illiquidity exemplifies why small investors can exploit opportunities"  
[X Link](https://x.com/LabbRadar/status/1742234658270515334)  2024-01-02T17:21Z [---] followers, [---] engagements


"Ironically it is the expertise of Wall Street's portfolio managers and investment analysts that serves as the explanation for the disappointing performance of their equity funds and stock recommendations. $NVCT"  
[X Link](https://x.com/anyuser/status/1742234659856044208)  2024-01-02T17:21Z [--] followers, [---] engagements


"$NVCT stands as a tangible example where due to specific circumstances the efficiency dogma will not apply"  
[X Link](https://x.com/anyuser/status/1742234665358884868)  2024-01-02T17:21Z [--] followers, [---] engagements


"Many illiquid biotech stocks exemplified by $NVCT exist below the institutional radar due to their size. These stocks flying under Wall Street's giant wings often escape systematic screening methods"  
[X Link](https://x.com/LabbRadar/status/1742234667133120807)  2024-01-02T17:21Z [---] followers, [---] engagements


"Wall Street primarily tracks a narrow selection of stocks. In contrast exchanges host thousands of companies. $NVCT's under-the-radar status driven by a small float and insider holdings aligns with the idea that smaller less-known stocks may be overlooked"  
[X Link](https://x.com/LabbRadar/status/1742234670501372339)  2024-01-02T17:21Z [----] followers, [---] engagements


"Greenblatt references Graham's strategy involving stocks selling below liquidation value. $NVCT mirrors this concept as its limited float restricts institutional buying"  
[X Link](https://x.com/LabbRadar/status/1742234672266960987)  2024-01-02T17:21Z [----] followers, [---] engagements


"@AaronRosenblum5 Thank you Aaron for this. Really solidifies the point Im trying to make about cult/overcrowded names especially in biotech do you know if he tracked/posted this chart of the most picked names for each year of the contest Thanks in advance"  
[X Link](https://x.com/LabbRadar/status/1742237374338248878)  2024-01-02T17:32Z [---] followers, [---] engagements


"Hey Twitter #biotech world 👋 I'm a 23-year-old investor with only 4-5 years experience investing $ in #bio. Realizing there's a ton to learn I'm on the lookout for a mentoranyone know a biotech fund manager or ace investor who might be up for mentoring/hiring me"  
[X Link](https://x.com/anyuser/status/1742313290217513404)  2024-01-02T22:33Z [--] followers, [---] engagements


"$HROW LADEN PT $34 Q3 results reveal a robust revenue of $34.3M marking a 50% YoY growth. Despite a slight dip from anticipated levels $HROW strategic launch of IHEEZO is outperforming internal estimates contributing to a 270% YoY increase in adjusted EBITDA to $9.2M"  
[X Link](https://x.com/anyuser/status/1743064240028610744)  2024-01-05T00:17Z [--] followers, [--] engagements


"$HROW maintains a solid financial standing with $65.6M in cash. Q3 earnings call highlights non-linear growth challenges but underscores confidence in 2023-2024 prospects. Lower earnings attributed to revenue estimates and increased costs from recent acquisitions"  
[X Link](https://x.com/LabbRadar/status/1743064244352876824)  2024-01-05T00:17Z [---] followers, [--] engagements


"However the breadth and scope of $BLCO's business may dilute their efforts compared to the more focused approach of $HROW"  
[X Link](https://x.com/LabbRadar/status/1743064260819693998)  2024-01-05T00:17Z [----] followers, [---] engagements


"$HROW The mention of a [--] million addressable patient pool in the DED space by $BLCO raises questions about hyperbole especially when contrasting it with the [--] million addressable market cited for VEVYE"  
[X Link](https://x.com/LabbRadar/status/1743064262874898567)  2024-01-05T00:17Z [----] followers, [---] engagements


"Presently $NVCT might be shadowing the broader trend set by $XBI and possibly facing shorts. However these dynamics are expected to decouple post data release emphasizing that the current market movement might not accurately reflect the intrinsic value"  
[X Link](https://x.com/LabbRadar/status/1743173056132939944)  2024-01-05T07:30Z [----] followers, [---] engagements


"$NVCT The current price despite its climb & subsequent drawdown is perceived to undervalue the stock due to its limited float inaccessible to institutions who cant buy shares of such an illiquid co"  
[X Link](https://x.com/LabbRadar/status/1743173057798160547)  2024-01-05T07:30Z [----] followers, [---] engagements


"$NVCT NXP800's role in inhibiting heat shock factor essentially curbing a survival gene for tumors while NXP900 serves as a solid inhibitor for tumors resistant to treatments like Astra Zeneca's Tagrisso adds immense value"  
[X Link](https://x.com/LabbRadar/status/1743173059425538474)  2024-01-05T07:30Z [---] followers, [---] engagements


"The possibility of acquisition by $AZN underscores the strategic allure. Not to mention $PFE may have interest in combo resistance of NXP900 w/ XTANDI. Could this lead to a bidding war down the road Hmmm 🤔 $NVCT"  
[X Link](https://x.com/LabbRadar/status/1743173061107384370)  2024-01-05T07:30Z [---] followers, [---] engagements


"Financially SLRN has a strong cash position but faces questions on operational efficiency. With substantial R&D expenses the recent trial hiccup raising some eyebrows. Understandably"  
[X Link](https://x.com/LabbRadar/status/1745137664255238587)  2024-01-10T17:36Z [---] followers, [---] engagements


"$TGTX TG Therapeutics dropped key updates at the 42nd Annual J.P. Morgan Healthcare Conference. Let's unpack the highlights and milestones projected for 2024: thread 🧵 (Im long the stock)"  
[X Link](https://x.com/anyuser/status/1745142151913013717)  2024-01-10T17:54Z [----] followers, [----] engagements


"More on BRIUMVI: BRIUMVI as a B-cell depleting therapy correlates with decreased immunoglobulin levels. Notably a decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients. $TGTX"  
[X Link](https://x.com/anyuser/status/1745142169420075150)  2024-01-10T17:54Z [--] followers, [---] engagements


"Continuous monitoring of quantitative serum immunoglobulins during treatment is crucial. In patients with opportunistic or recurrent infections vigilance is key. After therapy discontinuation monitor until B-cell repletion. $TGTX"  
[X Link](https://x.com/LabbRadar/status/1745142171051696574)  2024-01-10T17:54Z [---] followers, [---] engagements


"More $TGTX nuggets: 🧵"  
[X Link](https://x.com/LabbRadar/status/1745145167517265963)  2024-01-10T18:06Z [---] followers, [---] engagements


"$TGTX [----] million shares sold short surprising against [----] guidance. Anticipate positive market reception; details to follow post-earnings call"  
[X Link](https://x.com/LabbRadar/status/1745145170247704998)  2024-01-10T18:06Z [---] followers, [---] engagements


"Strategic Buyback Moves by $DTIL: Noteworthy 8K filing reveals a unique approach. $TGTX buying shares at 200% above VWAPdifferent from the previous announcement"  
[X Link](https://x.com/LabbRadar/status/1745515930652958969)  2024-01-11T18:40Z [---] followers, [---] engagements


"Outstanding Q4 Performance: Q4 revenue hits an impressive $40M. Projected $250M/year could lead to cash flow positivity. $TGTX"  
[X Link](https://x.com/anyuser/status/1745515932179665151)  2024-01-11T18:40Z [--] followers, [---] engagements


"Genocide is the deliberate act of eradicating a specific demographic through killing. Hamas openly acknowledges this objective in its charter and speeches. In contrast Israel not only condemns such actions but actively opposes them by evacuating civilians & facilitating"  
[X Link](https://x.com/LabbRadar/status/1745820667222561027)  2024-01-12T14:50Z [---] followers, [---] engagements


"humanitarian aid. Despite this some individuals sympathetic to Hamas propagate the misleading notion that Israel is engaging in genocidal activities"  
[X Link](https://x.com/LabbRadar/status/1745820668950659110)  2024-01-12T14:50Z [---] followers, [--] engagements


"$AVRO CEO resignation replaced by the CFO indicating a focus on the exit strategy. CFO with a decade in investment banking managed the Novartis sale. Activist firms bought 15% of the float showing confidence in Avrobio's potential. #ActivistInvestors"  
[X Link](https://x.com/LabbRadar/status/1745854413485297781)  2024-01-12T17:05Z [---] followers, [---] engagements


"$AVRO financials: $124 million in cash $90 million in money market funds and zero debt. Market cap is a mere $66 million. Cash burn reduced to an estimated $2.4 million per month. #FinancialHealth #CashRich"  
[X Link](https://x.com/LabbRadar/status/1745854415301431352)  2024-01-12T17:05Z [---] followers, [---] engagements


"$AVRO pipeline: Three programs paused focus on the Gaucher disease program in Phase 2/3 trials. Analysts estimate potential program value at $90 million in its current state. Cash per share: $2.34; Stock trading at $1.50"  
[X Link](https://x.com/LabbRadar/status/1745854417247645827)  2024-01-12T17:05Z [---] followers, [---] engagements


"$AVRO June quarter balance sheet showed a book value of $122 million. Adjusted economic book value around $128 million. Cost-cutting measures significantly reduced second-quarter cash burn to about $14 million"  
[X Link](https://x.com/LabbRadar/status/1745854426911285386)  2024-01-12T17:05Z [----] followers, [---] engagements


"Current MC $64M MRQ Cash $105M Q4 Burn Low $AVRO Im long"  
[X Link](https://x.com/LabbRadar/status/1745854461602373658)  2024-01-12T17:05Z [---] followers, [---] engagements


"Please like comment and retweet if you find this analysis insightful $AVRO $AXSM $MREO $PDSB $XAIR $TGTX $HROW $OCUL $LPTX $ARDX $LIFE $BLUE $MIST $SLRN $SRZN $CRBP $CLRB $CYTK $YMAB $TPTS $DMTK $XFOR $EFTR $VKTX $PRQR $XPON $INZY $NARI $DAWN $ARWR $CTMX $XBI $NTBL $UNCY $CRVS"  
[X Link](https://x.com/LabbRadar/status/1745854463204553102)  2024-01-12T17:05Z [---] followers, [----] engagements


"Fintwit - is there any way to get an interest free loan without some sketchy terms Do these exist Ive heard of interest free loans but there must be some sort of twist in the terms. Someone knowledgeable please shed some light. Happy Friday :)"  
[X Link](https://x.com/LabbRadar/status/1745963262678651215)  2024-01-13T00:17Z [---] followers, [---] engagements


"$MREO Safety Profile: ASTRAEUS showcased remarkable safety [--] exacerbation vs [--] in the placebo arm. Alvelestat's safety record impressivetested on [----] patients prior"  
[X Link](https://x.com/anyuser/status/1746649623857676567)  2024-01-14T21:44Z [--] followers, [---] engagements


"$MREO Short Interest Drop: Lowest since IPO1.4M shares. Expecting a quick deal. Recent stock surge without news hints at a brewing development"  
[X Link](https://x.com/LabbRadar/status/1746649625485017492)  2024-01-14T21:44Z [---] followers, [---] engagements


"An rDCF-based SOTP analysis suggests a $11 price target reflecting the potential success of CLR-131 in Waldenstrom's macroglobulinemia and relapsed/refractory multiple myeloma. $CLRB"  
[X Link](https://x.com/LabbRadar/status/1747300752773533862)  2024-01-16T16:52Z [---] followers, [---] engagements


"Like retweet comment follow me if you thought this thread & my other threads are helpful and informative :) $CLRB $AXSM $TSLA $ABUS $PDSB $LPTX $CRVS $XFOR $EFTR $MREO $TGTX $XAIR $PRQR $ARWR $OCUL $HROW $SLRN $MIST $LIFE $PFE $AZN $CRBP $NTBL $UNCY $MDXH $VKTX $CHRS $AMLX XBI"  
[X Link](https://x.com/LabbRadar/status/1747300754585493771)  2024-01-16T16:52Z [---] followers, [----] engagements


"@DrEliDavid They should just turn Gaza into Israels parking lot already - let the innocent Palestinians build their lives in Israel and kill the useless Hamas terrorists that have already cost the western world WAY too much money and agony"  
[X Link](https://x.com/anyuser/status/1747312562201317764)  2024-01-16T17:39Z [--] followers, [--] engagements


"$CLRB Addressing high-grade gliomas in pediatric patients an area with limited options positions them as a major BO contender. Iopofosine I 131's efficacy could redefine treatments"  
[X Link](https://x.com/LabbRadar/status/1754547639738413527)  2024-02-05T16:48Z [---] followers, [---] engagements


"$CLRB thanks for reading Cheers 🍻$AVRO $AXSM $MREO $PDSB $XAIR $TGTX $HROW $OCUL $LPTX $ARDX $LIFE $BLUE $MIST $SLRN $SRZN $CRBP $CLRB $CYTK $YMAB $TPTS $DMTK $XFOR $EFTR $VKTX $PRQR $XPON $INZY $NARI $DAWN $ARWR $CTMX $XBI $NTBL $UNCY $CRVS $AMZN $TSLA $GOOGL $GE $VLON $ASAN"  
[X Link](https://x.com/LabbRadar/status/1754547641705541916)  2024-02-05T16:48Z [---] followers, [----] engagements


"$NVCT Oppenheimer conference main takeaways: NXP800: - data coming in 1-1.5 months (preliminary small patient cohort) - planning seems to be beyond data readout are looking at other indications to expand into (signals the results are positive)"  
[X Link](https://x.com/LabbRadar/status/1757440417119826079)  2024-02-13T16:23Z [---] followers, [---] engagements


"$NVCT NXP900 (not as in depth) - one of a kind drug - was best drug that worked with Tagrisso study. Interested in pursuing collaborations with $AZN or $PFE for this compound given TAGRISSO and XTANDI resistance studies respectively"  
[X Link](https://x.com/LabbRadar/status/1757440419665793115)  2024-02-13T16:23Z [---] followers, [---] engagements


"@JamesEKrause Him being right on $OCUL builds my confidence that much more on $HROW"  
[X Link](https://x.com/LabbRadar/status/1758709835821134281)  2024-02-17T04:27Z [---] followers, [---] engagements


"Im hearing some rumours the 500K short is starting to cover 🧐 $NVCT"  
[X Link](https://x.com/LabbRadar/status/1762198367684149282)  2024-02-26T19:30Z [---] followers, [---] engagements


"$CLRB Despite these adverse events the study demonstrates the safety & tolerability of iopofosine I [---] in combination with 60-70 Gray of external beam radiation"  
[X Link](https://x.com/LabbRadar/status/1764734621479030869)  2024-03-04T19:28Z [---] followers, [---] engagements


"$CLRB Given the breaks between treatments the transient nature of these adverse events is noteworthy for highly refractory patients where survival takes precedence"  
[X Link](https://x.com/LabbRadar/status/1764734623353831542)  2024-03-04T19:28Z [---] followers, [---] engagements


"Analysts at Roth MKM maintain a positive outlook on $CLRB reiterating a Buy recommendation with a $20 target. The potential acquisition target status is highlighted considering the cos attractive profile in light of the study's success"  
[X Link](https://x.com/LabbRadar/status/1764734625186734456)  2024-03-04T19:28Z [---] followers, [---] engagements


"$NVCT This nascent insight imbues me with heightened certitude regarding the drug's latent potential notwithstanding the modest patient cohort constituting its maiden trial"  
[X Link](https://x.com/LabbRadar/status/1768710713659293757)  2024-03-15T18:47Z [----] followers, [---] engagements


"$NVCT Amidst my effervescent optimism a modicum of disappointment lingers due to the meager patient pool. However the drug's demonstrable efficacy remains resolute"  
[X Link](https://x.com/LabbRadar/status/1768710715806720393)  2024-03-15T18:47Z [----] followers, [---] engagements


"$SRZN no buyout coming anytime soon. Investors catching a dagger today"  
[X Link](https://x.com/LabbRadar/status/1774798899695206764)  2024-04-01T14:00Z [---] followers, [---] engagements


"@JoshuaHast95 @SelfThink4 I think it will be way bigger than $IMGN"  
[X Link](https://x.com/LabbRadar/status/1787876343163613389)  2024-05-07T16:05Z [----] followers, [--] engagements


"Added another $10K worth of shares to my core $NVCT pos. W/ the recent insider buys and the hopes of a Japan partnership agreement + data in August-September I am feeling optimistic. Best of luck to the other fellow $NVCT investors Ive had the privilege of getting to know :)"  
[X Link](https://x.com/LabbRadar/status/1793314105857659181)  2024-05-22T16:12Z [---] followers, [---] engagements


"As Pfizer pivots towards oncology to recover from a tough [----] the spotlight on $NVCT intensifies. Let's dissect why this acquisition could be a game-changer especially with the promising advancements in their pipeline. #Biotech #Oncology https://www.cnbc.com/2024/03/10/pfizer-is-betting-big-on-cancer-drugs-after-covid-decline.html https://www.cnbc.com/2024/03/10/pfizer-is-betting-big-on-cancer-drugs-after-covid-decline.html"  
[X Link](https://x.com/LabbRadar/status/1793691769600967021)  2024-05-23T17:13Z [---] followers, [---] engagements


"Pfizer is signaling financial robustness by cutting costs and buying back shares. This strategy paired with their goal to have 2/3rds of revenue from oncology by [----] positions them well for impactful acquisitions. $NVCT is right in their crosshairs"  
[X Link](https://x.com/LabbRadar/status/1793691771723235446)  2024-05-23T17:13Z [---] followers, [--] engagements


"Currently 20% of Pfizer's revenue is from genitourinary cancers. They aim to boost this to 35%. $NVCT's NXP900 particularly its synergies with Xtandi aligns perfectly with Pfizers objectives especially as Xtandi's patent expiry looms in [----]. #Pharma"  
[X Link](https://x.com/LabbRadar/status/1793691773581361269)  2024-05-23T17:13Z [---] followers, [--] engagements


"Despite Pfizer's pipeline being just 6% biologics they plan for it to hit 65% by [----]. $NVCT's small molecule inhibitors like NXP800 and NXP900 offer a compelling complement to this transition"  
[X Link](https://x.com/LabbRadar/status/1793691775309332769)  2024-05-23T17:13Z [---] followers, [--] engagements


"$NVCTs efficient trial pathway with ORR% endpoints allows for rapid advancement through Phases 1b and 2a. This streamlined approach keeps cash burn low while accelerating potential approvals. $NVCT"  
[X Link](https://x.com/LabbRadar/status/1793691792451514493)  2024-05-23T17:13Z [---] followers, [---] engagements


"Speculations about an Asian regional partnership add another layer of excitement. With unmet medical needs in oncology $NVCT is poised for strategic alliances with a Japanese fund"  
[X Link](https://x.com/LabbRadar/status/1793691794011521331)  2024-05-23T17:13Z [---] followers, [--] engagements


"Despite the Russell rebalance pressures $NVCT's resilience is evident today. The strategic actions and recent insider purchases by CEO Ron Bentsur and the team's clear vision bode well for investors"  
[X Link](https://x.com/LabbRadar/status/1793691795613950201)  2024-05-23T17:13Z [---] followers, [---] engagements


"Pfizers oncology pivot makes $NVCT a prime acquisition target for combo therapy w/ XTANDI. With their advanced trials institutional partnerships and strategic financial moves $NVCT aligns perfectly with Pfizer's long-term goals"  
[X Link](https://x.com/LabbRadar/status/1793691797367275626)  2024-05-23T17:13Z [---] followers, [---] engagements


"@RNAiAnalyst The $300M offering by DYN led by Morgan Stanley reveals intriguing insights especially considering Morgan Stanley's consistent increase in their $ARWR position while adjusting price targets arbitrarily. #FollowTheMoney #MarketMovers"  
[X Link](https://x.com/LabbRadar/status/1796573575534768211)  2024-05-31T16:04Z [----] followers, [--] engagements


"@RNAiAnalyst $ARWR's confidence is bolstered by the success of $ALNY's liver-targeted RNAi drugs. However the challenge lies in securing sufficient capital to fund their expansive pipeline targeting various tissues. #BiotechChallenges #Investment"  
[X Link](https://x.com/LabbRadar/status/1796573687141024203)  2024-05-31T16:05Z [----] followers, [--] engagements


"🧵 THREAD: The Future of $VKTX and Its Blockbuster Potential in the Oral GLP-1 Market"  
[X Link](https://x.com/anyuser/status/1800037663795453975)  2024-06-10T05:29Z [----] followers, 25.4K engagements


"With oral GLP-1s alone estimated at a $50B total addressable market $VKTXs VK2735 presents a significant opportunity. Considering 20-30% of patients may not tolerate existing GLP-1s from $LLY and $NVO theres a $30B+ market for alternatives. Could VK2735 capture this $VKTX"  
[X Link](https://x.com/LabbRadar/status/1800037666240790637)  2024-06-10T05:29Z [----] followers, [----] engagements


"Future Catalysts: July: Oral data for 60mg dose cohort. Obesity Conference: Full data presentation for high-dose oral drug cohorts. Year-End 2024: Start of either Phase 2B or Phase [--] for SubQ formulation contingent on FDA feedback. $VKTX"  
[X Link](https://x.com/LabbRadar/status/1800037678307549534)  2024-06-10T05:30Z [----] followers, [----] engagements


"Big pharmas interest is keen considering the efficacy and tolerability of VK2735. $PFE $AZN and others may find it more prudent to acquire $VKTX rather than develop lagging internal candidates"  
[X Link](https://x.com/LabbRadar/status/1800037680056619264)  2024-06-10T05:30Z [----] followers, [----] engagements


"The potential yearly sales (PYS) in obesity alone could generate substantial revenue aligning with the market's increasing demand. The strategic value for large biopharma companies becomes evident here. $VKTX"  
[X Link](https://x.com/LabbRadar/status/1800037691532235044)  2024-06-10T05:30Z [----] followers, [----] engagements


"Big pharma like $PFE $MRK and $AZN have historically made numerous suboptimal acquisitions. Despite this they lag behind $LLY in MC due to the success of GLP-1 technologies. Rather than acquiring $VKTX which boasts superior GLP-1 tech they continue developing their own"  
[X Link](https://x.com/LabbRadar/status/1800037693646323829)  2024-06-10T05:30Z [----] followers, [---] engagements


"trailing in both toxicity and efficacy which makes absolutely no rational sense; I still cannot understand the logic here. $AZN $MRK $PFE $VKTX"  
[X Link](https://x.com/LabbRadar/status/1800037695571337563)  2024-06-10T05:30Z [----] followers, [---] engagements


"$PFE CEO projects a $30B market for oral GLP-1s a fraction of the total obesity market estimated to exceed $100B. This underlines the vast potential market share $VKTX could capture with its best-in-class solutions"  
[X Link](https://x.com/LabbRadar/status/1800037697341276160)  2024-06-10T05:30Z [----] followers, [----] engagements


"$VKTX appears to be the safest most effective and quickest option in the early-phase data among GLP-1 competitors. However the rapid data flow and evolving profiles make it challenging for both $VKTX and potential acquirers to predict the best long-term bets"  
[X Link](https://x.com/LabbRadar/status/1800037699254198619)  2024-06-10T05:30Z [----] followers, [----] engagements


"For a potential acquisition cost of $25B an acquirer would gain access to: Leading NASH treatments. Innovative obesity solutions. X-ALD treatments. Muscle mass improvement therapies (VK2511). All of which have potential best-in-class (BIC) profiles. $VKTX"  
[X Link](https://x.com/LabbRadar/status/1800037702265458933)  2024-06-10T05:30Z [----] followers, [---] engagements


"The acquirer would see an immediate increase in market cap. For instance $MRK with a $330B market cap could integrate $VKTXs pipeline positioning itself competitively against $LLY and $NVO potentially leading the obesity and NASH markets in a few years. $VKTX"  
[X Link](https://x.com/LabbRadar/status/1800037703817339363)  2024-06-10T05:30Z [----] followers, [----] engagements


"With patents extending through [----] $VKTX offers long-term value stability making it an attractive acquisition target for large biopharma companies seeking to solidify their market position"  
[X Link](https://x.com/LabbRadar/status/1800037705536971179)  2024-06-10T05:30Z [----] followers, [---] engagements


"As $VKTX navigates through its clinical trials & regulatory milestones strategic partnerships or acquisitions could significantly alter its mkt trajectory. Investors should closely monitor upcoming FDA meetings & clinical data releases for potential game-changing announcements"  
[X Link](https://x.com/LabbRadar/status/1800037707294335156)  2024-06-10T05:30Z [----] followers, [----] engagements


"$VKTX portfolio and strategic position make it a standout in the biopharma landscape. Whether through partnerships or acquisition its potential to redefine the obesity and NASH markets cannot be overstated. This is a stock to watch for both long-term growth & strategic M&A"  
[X Link](https://x.com/LabbRadar/status/1800037709110448179)  2024-06-10T05:30Z [----] followers, [----] engagements


"Upcoming Data Release: The ORBIT Phase [--] study data is expected in the second half of the year with a 14-month update anticipated around mid-year. This follows the October '23 update which showed promising results after six to nine months of treatment. $MREO"  
[X Link](https://x.com/LabbRadar/status/1800337156306604046)  2024-06-11T01:20Z [----] followers, [---] engagements


"Impressively [--] out of [--] patients remain in the trial some for as long as [--] months with no serious adverse events reported including cardiovascular issues. This is notable given the cardiovascular risks seen with Amgen's romosozumab in osteoporosis trials. $MREO $AMGN"  
[X Link](https://x.com/LabbRadar/status/1800337158445965699)  2024-06-11T01:20Z [----] followers, [---] engagements


"$MREO With its strong safety profile and consistent efficacy Setrusumab is poised for approval for chronic use potentially transforming the therapeutic landscape for OI a condition currently lacking approved treatments"  
[X Link](https://x.com/LabbRadar/status/1800337180235325778)  2024-06-11T01:20Z [----] followers, [---] engagements


"Alvelestat licensed from $AZN showed significant improvements in FEV1 and close to significant results on SVC in a small four-week trial for bronchiectasis. This positive data is supported by its mechanism of action targeting neutrophil elastase. $MREO"  
[X Link](https://x.com/LabbRadar/status/1800337182625812949)  2024-06-11T01:20Z [----] followers, [---] engagements


"$MREO OI is a group of genetic disorders characterized by weak bones & high fracture risk affecting approx 60k individuals in the U.S & EU. Setrusumabs dual mechanism of action to stimulate bone formation & inhibit resorption positions it as a potentially transformative therapy"  
[X Link](https://x.com/LabbRadar/status/1800337193866785000)  2024-06-11T01:20Z [----] followers, [---] engagements


"In December [----] $MREO partnered with Ultragenyx ($RARE) for Setrusumab with $RARE funding development and $MREO retaining EU rights. This partnership underscores the high value and strong data supporting Setrusumabs success. $MREO"  
[X Link](https://x.com/LabbRadar/status/1800337195967934833)  2024-06-11T01:20Z [----] followers, [---] engagements


"Analysts estimate a 60-65% probability of success for Setrusumab in both the U.S. and EU with peak sales projections of $1.5 billion and $1 billion respectively. Approval in these regions could generate substantial revenue for both $MREO and $RARE"  
[X Link](https://x.com/LabbRadar/status/1800337198073684455)  2024-06-11T01:20Z [----] followers, [---] engagements


"On the other side Acerta Pharma founded by former Pharmacyclics employees develops another BTK inhibitor Calquence. Their story epitomizes the fierce competition and innovation driving the biotech sector"  
[X Link](https://x.com/LabbRadar/status/1800925021789176014)  2024-06-12T16:15Z [----] followers, [---] engagements


"Vardi delves into the financial rollercoaster accompanying drug development. Pharmacyclics' rise culminates in a $21 billion acquisition by AbbVie while Acerta Pharmas success leads to a multibillion-dollar deal with $AZN"  
[X Link](https://x.com/LabbRadar/status/1800925024100213126)  2024-06-12T16:15Z [----] followers, [---] engagements


"@pacha_8x I leave on Monday but I am from Canada myself will let you know if Im in Toronto ever"  
[X Link](https://x.com/LabbRadar/status/1806770297736949942)  2024-06-28T19:23Z [----] followers, [--] engagements


"They were part of the wave of Eastern European Jewish immigrants seeking a better life in the United States. Abraham worked as a presser in the garment industry a common occupation for Jewish immigrants at the time"  
[X Link](https://x.com/LabbRadar/status/1807444222905053202)  2024-06-30T16:00Z [----] followers, [--] engagements


"The working conditions in the garment factories of the early 20th century especially in places like New York City's Lower East Side were often extremely harsh and unjust. The factories often referred to as sweatshops were characterized by:"  
[X Link](https://x.com/LabbRadar/status/1807444226575044677)  2024-06-30T16:00Z [----] followers, [--] engagements


"Workers formed and joined labor unions such as the International Ladies' Garment Workers' Union (ILGWU) and the Amalgamated Clothing Workers of America (ACWA). These unions played a crucial role in advocating for workers' rights and better conditions"  
[X Link](https://x.com/LabbRadar/status/1807444232908460044)  2024-06-30T16:01Z [----] followers, [--] engagements


"One of the most significant actions was the Uprising of the [-----] in [----] a massive strike by predominantly female garment workers in New York City. This strike which lasted for over two months demanded better pay shorter hours and safer working conditions"  
[X Link](https://x.com/LabbRadar/status/1807444234267443645)  2024-06-30T16:01Z [----] followers, [--] engagements


"After Abraham's death Fannie had to find ways to support her family highlighting the resilience & determination of many immigrant families"  
[X Link](https://x.com/LabbRadar/status/1807444255054475332)  2024-06-30T16:01Z [----] followers, [--] engagements


"The Tenement Museum's portrayal of the Rogarshevsky family provided me with a vivid and personal glimpse into the lives of early 20th-century Jewish immigrants in New York City demonstrating both the struggles and the sense of community that characterized their experience"  
[X Link](https://x.com/LabbRadar/status/1807444256677662959)  2024-06-30T16:01Z [----] followers, [--] engagements


"$ENTB BIO89-100 targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) addressing significant unmet medical needs in these areas"  
[X Link](https://x.com/LabbRadar/status/1811147005105951044)  2024-07-10T21:14Z [----] followers, [---] engagements


"$ENTB BIO89-100 is a glycoPEGylated analog of fibroblast growth factor [--] (FGF21) designed for once-weekly dosing. FGF21 is a key regulator of lipid & glucose metabolism energy homeostasis & insulin sensitivity making it a promising candidate for treating metabolic disorders"  
[X Link](https://x.com/LabbRadar/status/1811147008192958914)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB NASH: Phase 2b ENLIVEN Trial: This ongoing study evaluates the efficacy and safety of BIO89-100 in patients with NASH"  
[X Link](https://x.com/LabbRadar/status/1811147011309326361)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Endpoints: Primary endpoints include the reduction of liver fat content and improvement in histological endpoints (NAS fibrosis stage)"  
[X Link](https://x.com/LabbRadar/status/1811147014098629109)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Interim Results: Positive interim results have shown significant reductions in liver fat and key biomarkers positioning BIO89-100 as a leading candidate in the NASH space"  
[X Link](https://x.com/LabbRadar/status/1811147016921305155)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB SHTG Phase [--] Trial: Evaluates the safety & efficacy of BIO89-100 in patients w/ severe hypertriglyceridemia. Endpoints: Primary endpoints focus on the reduction of triglyceride levels"  
[X Link](https://x.com/LabbRadar/status/1811147020008313189)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Prelim Data: Demonstrated reductions in triglyceride levels with favorable tolerability and safety profile highlighting its potential in addressing SHTG"  
[X Link](https://x.com/LabbRadar/status/1811147023200178202)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Efficacy: BIO89-100 has shown compelling efficacy in reducing liver fat & triglyceride levels crucial for treating NASH and SHTG respectively. Safety: Safety profile remains favorable w/ once-weekly dosing offering convenience & adherence benefits over daily treatments"  
[X Link](https://x.com/LabbRadar/status/1811147026283032628)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB NASH: A rapidly growing market with estimates reaching $35 billion by [----]. The lack of approved treatments makes BIO89-100 a potential blockbuster"  
[X Link](https://x.com/LabbRadar/status/1811147029911064824)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB SHTG: Addressing a significant unmet need the global SHTG market presents substantial revenue opportunities with BIO89-100 well-positioned to capture significant market share"  
[X Link](https://x.com/LabbRadar/status/1811147032650011033)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB has been proactive in forming strategic alliances to enhance the development and commercialization of BIO89-100. These collaborations are expected to accelerate clinical development and expand market reach"  
[X Link](https://x.com/LabbRadar/status/1811147035493769525)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Upcoming Catalysts: Phase 2b ENLIVEN Trial Data: Top-line results anticipated in [----] will be a critical milestone potentially validating BIO89-100's efficacy and safety in NASH"  
[X Link](https://x.com/LabbRadar/status/1811147038182256826)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Regulatory Pathways: Successful phase [--] trials could pave the way for pivotal phase [--] studies bringing BIO89-100 closer to potential approval and commercialization"  
[X Link](https://x.com/LabbRadar/status/1811147041768362163)  2024-07-10T21:14Z [----] followers, [--] engagements


"Additionally $ENTB's latest Phase 2b ENLIVEN study showcases pegozafermin's potential in treating metabolic dysfunction-associated steatohepatitis (NASH) with fibrosis. #Biotech #Investing"  
[X Link](https://x.com/LabbRadar/status/1811147044545069230)  2024-07-10T21:14Z [----] followers, [--] engagements


"Pegozafermin an engineered FGF21 analog boasts a significantly extended half-life (55-100h) compared to native FGF21 (1-2h). This enhancement is achieved through glycoPEGylation which prevents C-terminal degradation and maintains structural integrity. #BiotechInnovation $ENTB"  
[X Link](https://x.com/LabbRadar/status/1811147048294699022)  2024-07-10T21:14Z [----] followers, [--] engagements


"The ENLIVEN trial design involved patients with F2-F3 NASH and a NAFLD Activity Score (NAS) [--]. The primary endpoints were 1-stage fibrosis improvement and NASH resolution without worsening fibrosis. #ClinicalTrials #NASH $ENTB"  
[X Link](https://x.com/LabbRadar/status/1811147051432038517)  2024-07-10T21:14Z [----] followers, [--] engagements


"Key findings at Week 24: $ENTB 26% of patients on 30mg QW pegozafermin saw fibrosis improvement without NASH worsening. 27% on 44mg Q2W pegozafermin experienced NASH resolution without fibrosis worsening. #LiverHealth"  
[X Link](https://x.com/LabbRadar/status/1811147055295025470)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Long-term benefits at Week [--] include: 60% median relative reduction in liver fat for the 30mg QW group. 47% median relative reduction for the 44mg Q2W group measured by MRI-PDFF. #LiverFatReduction"  
[X Link](https://x.com/LabbRadar/status/1811147060290408946)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Pegozafermin also demonstrated significant reductions in liver injury markers: ALT reduced by 42% and 35% for the 30mg QW and 44mg Q2W groups respectively. AST decreased by 39% and 36% in the same groups. #LiverHealth"  
[X Link](https://x.com/LabbRadar/status/1811147064686035335)  2024-07-10T21:14Z [----] followers, [---] engagements


"$ENTB In terms of metabolic improvements the study noted: 21% reduction in non-HDL-C for the 30mg QW group. 18% reduction in triglycerides for the 44mg Q2W group. HbA1c levels showed notable improvements. #MetabolicHealth"  
[X Link](https://x.com/LabbRadar/status/1811147069291446490)  2024-07-10T21:14Z [----] followers, [--] engagements


"$ENTB Even patients re-randomized from placebo to pegozafermin showed continued benefit: MRI-PDFF decreased by 63% at Week [--]. Significant reductions in ALT and AST were observed. #ClinicalSuccess"  
[X Link](https://x.com/LabbRadar/status/1811147073850593387)  2024-07-10T21:14Z [----] followers, [---] engagements


"$ENTB Safety profile: Pegozafermin was well tolerated across all dosages. Most treatment-emergent adverse events (TEAEs) were mild to moderate with no significant changes in blood pressure bone biomarkers or DXA observed. #SafetyFirst"  
[X Link](https://x.com/LabbRadar/status/1811147078237909104)  2024-07-10T21:14Z [----] followers, [---] engagements


"With these promising results $ENTB pegozafermin stands out as a potential game-changer in NASH treatment offering both efficacy and a favorable safety profile"  
[X Link](https://x.com/LabbRadar/status/1811147081555529813)  2024-07-10T21:14Z [----] followers, [---] engagements


"Bought $VYNE last Friday at $1.81"  
[X Link](https://x.com/LabbRadar/status/1811453646821044323)  2024-07-11T17:32Z [----] followers, [---] engagements


"$NVCT Ken Hoberman (Director): Mr. Hoberman joined the Board of Directors in July [----]. He brings extensive financial investor relations corporate governance operational and business development experience including M&A strategic alliances and partnerships"  
[X Link](https://x.com/LabbRadar/status/1811480137290121720)  2024-07-11T19:18Z [----] followers, [--] engagements


"$NVCT As the Chief Operating Officer of Stemline Therapeutics since [----] Mr. Hoberman helped lead the company from an early-stage drug development company to a fully integrated commercial entity including through its successful initial public offering"  
[X Link](https://x.com/LabbRadar/status/1811480140100305155)  2024-07-11T19:18Z [----] followers, [---] engagements


"$NVCT He also led the M&A transaction resulting in the acquisition of Stemline by the Menarini Group in June 2020"  
[X Link](https://x.com/LabbRadar/status/1811480142700773488)  2024-07-11T19:18Z [----] followers, [--] engagements


"$NVCT Previously he was Vice President of Corporate and Business Development at Keryx Biopharmaceuticals where he led the company's business strategy for Auryxia including its in-licensing and Japanese partnership. Little bit of foreshadowing here w/ hopes of Japan partnership"  
[X Link](https://x.com/LabbRadar/status/1811480145179672602)  2024-07-11T19:18Z [----] followers, [--] engagements


"$NVCT Mr. Hoberman is also on the Board of Directors of TG Therapeutics Inc. $TGTX"  
[X Link](https://x.com/LabbRadar/status/1811480147859779719)  2024-07-11T19:18Z [----] followers, [---] engagements


"$NVCT At MD Anderson Cancer Center she directs Early Drug Development and Phase I Trials and co-directs the Ovarian Cancer Moonshot program"  
[X Link](https://x.com/LabbRadar/status/1811480166461551085)  2024-07-11T19:18Z [----] followers, [--] engagements


"$NVCT Her leadership extends to co-PI roles in Uterine and Ovarian Cancer SPORE projects and she is a co-chair of the NCI GCSC Ovarian Cancer Task Force. Her work is pivotal in driving innovative clinical trials in gynecologic cancers"  
[X Link](https://x.com/LabbRadar/status/1811480169460412862)  2024-07-11T19:18Z [----] followers, [--] engagements


"Continuation of Bull Thesis (Current price is $10): $CORZ $SQ https://x.com/LabbRadar/status/1811868540112376292 $CORZ (Bull Thesis): Currently trading at $10 https://x.com/LabbRadar/status/1811868540112376292 $CORZ (Bull Thesis): Currently trading at $10"  
[X Link](https://x.com/LabbRadar/status/1811869617687789907)  2024-07-12T21:05Z [----] followers, [---] engagements


"$CORZ recently expanded its hosting agreement with CoreWeave expected to generate an additional $1.225 billion in cumulative revenue. These developments underscore the company's growth strategy"  
[X Link](https://x.com/LabbRadar/status/1811869621500412029)  2024-07-12T21:05Z [----] followers, [---] engagements


"As $CORZ & $SQ forge a partnership to enhance bitcoin mining efficiency with advanced technology it's worth noting the financial metrics and expert analysis that might shape Core Scientific's trajectory"  
[X Link](https://x.com/LabbRadar/status/1811869623291380133)  2024-07-12T21:05Z [----] followers, [---] engagements


"$CORZ With an adjusted market capitalization of $1.7 billion USD and a significant quarterly revenue growth of 48.6% in Q1 [----] Core Scientific is showing signs of robust expansion. $SQ"  
[X Link](https://x.com/LabbRadar/status/1811869625141039573)  2024-07-12T21:05Z [----] followers, [---] engagements


"$ARVN (Bull Thesis): current price = $28"  
[X Link](https://x.com/LabbRadar/status/1811899267474424278)  2024-07-12T23:03Z [----] followers, [---] engagements


"$ARVN has been making significant strides in the biotech industry especially with their pioneering PROTAC technology"  
[X Link](https://x.com/LabbRadar/status/1811899269450014801)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN's oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models"  
[X Link](https://x.com/LabbRadar/status/1811899271492567509)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN's vepdegestrant targets estrogen receptor (ER) alpha signaling a known driver of ER-positive/human epidermal growth factor receptor [--] negative (ER+/HER2-) breast cancer"  
[X Link](https://x.com/LabbRadar/status/1811899273442931199)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN This innovative approach aims to address suboptimal ER inhibition and resistance due to ESR1 mutation which current endocrine therapies struggle to overcome"  
[X Link](https://x.com/LabbRadar/status/1811899275447795932)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN In preclinical studies vepdegestrant induced over 90% degradation of both wild-type and mutant ER outperforming the standard ET agent fulvestrant which achieved only 31-80% tumor growth inhibition (TGI)"  
[X Link](https://x.com/LabbRadar/status/1811899277435924688)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN The impressive preclinical performance of vepdegestrant was evident as it achieved significant tumor regressions in hormone-independent ER Y537S patient-derived xenograft (PDX) models showing efficacy even in the palbociclib-resistant model"  
[X Link](https://x.com/LabbRadar/status/1811899279419802074)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN's vepdegestrant has shown robust efficacy in combination with CDK4/6 inhibitors like palbociclib abemaciclib and ribociclib as well as mTOR and PI3K inhibitors such as everolimus alpelisib and inavolisib"  
[X Link](https://x.com/LabbRadar/status/1811899281344987571)  2024-07-12T23:03Z [----] followers, [---] engagements


"The superior in-vivo ER degradation by vepdegestrant compared to fulvestrant (90% vs. 63-65%) correlates with improved tumor growth inhibition suggesting that $ARVN's therapy could become a more effective backbone endocrine therapy for ER+/HER2- breast cancer patients"  
[X Link](https://x.com/LabbRadar/status/1811899283215643031)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN's pioneering work with PROTAC molecules showcases their ability to degrade disease-causing proteins which were previously considered undruggable"  
[X Link](https://x.com/LabbRadar/status/1811899285111476463)  2024-07-12T23:03Z [----] followers, [--] engagements


"The development and preclinical success of vepdegestrant underscore $ARVN's commitment to advancing cancer therapies"  
[X Link](https://x.com/LabbRadar/status/1811899287007297640)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN continues to set new standards in the biotech industry with their novel therapies. The potential of vepdegestrant to provide enhanced efficacy and durability of response could transform the treatment landscape for patients with ER+/HER2- breast cancer"  
[X Link](https://x.com/LabbRadar/status/1811899289062490504)  2024-07-12T23:03Z [----] followers, [--] engagements


"$ARVN's recent study on 2L treatments for HR+/HER2- locally advanced or metastatic breast cancer (LABC/mBC) after 1L CDK4/6 inhibitor therapy. The study published in BMC Cancer provides valuable real-world insights. #Biotech #CancerResearch"  
[X Link](https://x.com/LabbRadar/status/1811899291050643961)  2024-07-12T23:03Z [----] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing